Lutetium-177 DOTATATE: A Practical Review.

Angela Y Jia, Rojano Kashani, Nicholas G Zaorsky, Daniel E Spratt, Ana P Kiess, Jeff M Michalski, Jacqueline E Zoberi, Hyun Kim, Brian C Baumann

Journal: Practical radiation oncology 2022;12(4):305-311

PMID: 35717045

Full Text on Elsevier Science View on PubMed

Abstract

Neuroendocrine tumors (NETs) are a heterogeneous group of tumors that originate in endocrine tissues throughout the body. Though most are indolent, clinical outcomes vary greatly based on histologic differentiation and grade. Peptide receptor radionuclide therapy has emerged as a promising treatment for patients with locally advanced and/or metastatic disease refractory to standard of care treatment. The phase III NETTER-1 trial found that [Lu] Lu-DOTA-[Tyr]-octreotate improved disease-free survival versus octreotide alone for somatostatin receptor-positive gastroenteropancreatic NETs and had a favorable toxicity profile, leading to Food and Drug Administration approval. [Lu] Lu-DOTA-[Tyr]-octreotate is an important new treatment that expands the role of radiation in the treatment of NETs. Several important trials are ongoing to better elucidate the role of this treatment.

Address: Department of Radiation Oncology, Johns Hopkins University, Baltimore, Maryland. Electronic address: [email protected].; Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio.; Department of Radiation Oncology, Johns Hopkins University, Baltimore, Maryland.; Department of Radiation Oncology, Washington University School of Medicine in St. Louis, St. Louis, Missouri.

DOI: 10.1016/j.prro.2022.02.002

Link outs

Free resources

Miscellaneous:

https://assays.cancer.gov/CPTAC-174

Subscription / membership required

Full Text Sources:

MeSH Terms: Humans, Lutetium, Neuroendocrine Tumors, Octreotide, Positron-Emission Tomography, Radioisotopes, Radionuclide Imaging, Radiopharmaceuticals